Place of care and costs associated with acute episodes and remission in schizophrenia

被引:0
|
作者
McIntyre, Roger S. [1 ]
Higa, Sara [2 ]
Doan, Quan, V [3 ]
Amari, Diana T. [3 ]
Mercer, Daniel [3 ]
Gillard, Patrick [2 ]
Harrington, Amanda [2 ]
机构
[1] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[2] AbbVie, Irvine, CA USA
[3] Genesis Res, Hoboken, NJ USA
来源
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2023年 / 29卷 / 05期
关键词
ANTIPSYCHOTIC MEDICATION; ECONOMIC BURDEN; ATYPICAL ANTIPSYCHOTICS; NONADHERENCE; PREDICTORS; ADHERENCE; RELAPSE;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Schizophrenia imposes significant economic burden on patients, families, caregivers, and society. To our knowledge, place of care and associated costs of acute schizophrenia episodes have not been well characterized.OBJECTIVE: To describe the care settings and costs associated with likely acute episodes and untreated remission periods among patients with schizophrenia. METHODS: Adults with schizophrenia were identified using the IBM MarketScan Commercial and Medicare Supplemental databases (2009-2018); claims for capitated benefits plans were excluded. Acute episode index date was defined as at least 1 inpatient schizophrenia claim or outpatient schizophrenia claim (frequency of claim dependent on visit type, such as hospitalization, emergency department, private practice, clinic, urgent care, or labora-tory). Mental health-related medical costs (health plan+patient) associated with acute episodes were collected over a 2-month follow-up period and stratified by setting (inpatient vs outpatient); acute episode data were reported in subgroups of patients without or with prior clozapine use, as an indication of disease severity. Remission index date was defined as at least 1 outpa-tient claim with a schizophrenia diagnosis with no acute episode and no oral or inject-able antipsychotic therapy. Remission costs were assessed over a 3-month period. All data were analyzed descriptively.RESULTS: A total of 14,824 patients with schizophrenia met criteria for an acute episode (12,896 [87.0%] without prior clo-zapine use; 1,427 [9.6%] with prior clozapine use). Most acute episodes were treated in an outpatient setting (all patients, 76.3%; without prior clozapine use, 74.5%; with prior clozapine use, 87.1%). When treated inpatient, mean (SD) episode medical costs were $17,045 ($28,101) for all patients, $16,060 ($22,786) for those without prior clozapine use, and $22,827 ($55,860) for those with prior clozapine use. When treat-ed outpatient, mean (SD) medical costs for acute episodes were $2,478 ($6,961) for all patients, $2,609 ($7,068) for those without prior clozapine use, and $1,770 ($6,560) for those with prior clozapine use. For all patients with acute episodes, regardless of clozapine use, patient-incurred out-of-pocket costs were approximately 30% of total medical costs. For an untreated period of remission, 6,950 patients with schizophrenia met criteria. Total medical costs were $2,399 for these patients over a 3-month period.CONCLUSIONS: The majority of acute schizophrenia episodes were treated in the outpatient setting. For episodes that required inpatient care, inpatient episodes were approximately 7 times more costly than episodes treated in outpatient-only settings. For acute episodes and remission periods, health plans covered most costs; however, there were additional patient -incurred out-of-pocket costs.
引用
收藏
页码:499 / 508
页数:10
相关论文
共 50 条
  • [31] Direct medical costs associated with schizophrenia relapses in health care services in the city of Sao Paulo
    Daltio, Claudiane Salles
    Mari, Jair Jesus
    Ferraz, Marcos Bosi
    REVISTA DE SAUDE PUBLICA, 2011, 45 (01): : 14 - 23
  • [32] Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia?
    Pilon, Dominic
    El Khoury, Antoine C.
    Manceur, Ameur M.
    Zhdanava, Maryia
    Benson, Carmela
    Lefebvre, Patrick
    Doshi, Jalpa A.
    POPULATION HEALTH MANAGEMENT, 2020, 23 (03) : 234 - 242
  • [33] HEALTH CARE COSTS ASSOCIATED WITH ACUTE CARDIOVASCULAR EVENTS IN A COPD PATIENT POPULATION
    Zueger, P. M.
    Lee, T. A.
    VALUE IN HEALTH, 2014, 17 (03) : A111 - A111
  • [34] Appropriateness of thrombophilia testing in patients in the acute care setting and an evaluation of the associated costs
    Virparia, Riddhi
    Brunetti, Luigi
    Vigdor, Stuart
    Adams, Christopher D.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 49 (01) : 108 - 112
  • [35] Appropriateness of thrombophilia testing in patients in the acute care setting and an evaluation of the associated costs
    Riddhi Virparia
    Luigi Brunetti
    Stuart Vigdor
    Christopher D. Adams
    Journal of Thrombosis and Thrombolysis, 2020, 49 : 108 - 112
  • [37] Depressive symptoms among patients with schizophrenia in acute and remission phases
    Peljto, Amir
    Pesic, Danilo
    Christodoulou, Nikos G.
    Tosevski, Dusica Lecic
    VOJNOSANITETSKI PREGLED, 2018, 75 (09) : 849 - 855
  • [38] Costs and recurrences of chiropractic and medical episodes of low-back care
    Smith, M
    Stano, M
    JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, 1997, 20 (01) : 5 - 12
  • [39] COSTS OF EPISODES OF CARE FOR ALLOGENEIC TRANSPLANT FOR THE THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY IN THE US
    Paramore, C.
    Dietz, A.
    Boulanger, L.
    VALUE IN HEALTH, 2020, 23 : S268 - S268
  • [40] COMPARING THE COSTS BETWEEN PROVIDER TYPES OF EPISODES OF BACK PAIN CARE
    SHEKELLE, PG
    MARKOVICH, M
    LOUIE, R
    SPINE, 1995, 20 (02) : 221 - 226